79 related articles for article (PubMed ID: 20032406)
21. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
[TBL] [Abstract][Full Text] [Related]
22. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
Brama M; Basciani S; Cherubini S; Mariani S; Migliaccio S; Arizzi M; Rosano G; Spera G; Gnessi L
Endocr Relat Cancer; 2007 Mar; 14(1):61-72. PubMed ID: 17395975
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
24. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
[TBL] [Abstract][Full Text] [Related]
25. Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
Prunotto M; Bosco M; Daniele L; Macri' L; Bonello L; Schirosi L; Rossi G; Filosso P; Mussa B; Sapino A
Lung Cancer; 2009 May; 64(2):244-6. PubMed ID: 19041155
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
28. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
29. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
30. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
31. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
32. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
[TBL] [Abstract][Full Text] [Related]
33. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
Hägerstrand D; Hesselager G; Achterberg S; Wickenberg Bolin U; Kowanetz M; Kastemar M; Heldin CH; Isaksson A; Nistér M; Ostman A
Oncogene; 2006 Aug; 25(35):4913-22. PubMed ID: 16547494
[TBL] [Abstract][Full Text] [Related]
34. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
35. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
[TBL] [Abstract][Full Text] [Related]
36. [In vitro killing effects of STI571 on esophageal carcinoma cell lines CE-48T and CE-81T].
Zhang PY; Li BJ; Su XD; Wen ZS; Zhao JM; Zhang LJ; Long H; Rong TH
Ai Zheng; 2006 Apr; 25(4):456-60. PubMed ID: 16613680
[TBL] [Abstract][Full Text] [Related]
37. Imatinib: a targeted clinical drug development.
Capdeville R; Silberman S
Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
[TBL] [Abstract][Full Text] [Related]
38. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
[TBL] [Abstract][Full Text] [Related]
40. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]